Impact of the Complement C3 Inhibitor Pegcetacoplan on Photoreceptor Degeneration beyond Areas of Geographic Atrophy in the FILLY Trial (MS 2022) - Apellis Medical Hub Canada

Impact of the Complement C3 Inhibitor Pegcetacoplan on Photoreceptor Degeneration beyond Areas of Geographic Atrophy in the FILLY Trial

Share Via Email

Back to Conference Resources

GA Congress Presentations Macula Society 2022

The following information is available for educational purposes only. The information is not to be re-purposed or re-used in its current form or presentation for any personal or professional use. Apellis reserves the right to withdraw, modify or change the information that is available on this website at any time.